JPMorgan Chase & Co. Raises Stake in Regulus Therapeutics Inc. (NASDAQ:RGLS)

JPMorgan Chase & Co. lifted its stake in Regulus Therapeutics Inc. (NASDAQ:RGLS) by 193.4% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 78,972 shares of the biopharmaceutical company’s stock after buying an additional 52,059 shares during the period. JPMorgan Chase & Co. owned approximately 0.12% of Regulus Therapeutics worth $124,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. Point72 Asset Management L.P. bought a new position in shares of Regulus Therapeutics in the third quarter worth approximately $1,403,000. NEA Management Company LLC purchased a new position in shares of Regulus Therapeutics in the third quarter valued at about $10,154,000. Barclays PLC raised its stake in shares of Regulus Therapeutics by 285.2% during the third quarter. Barclays PLC now owns 84,477 shares of the biopharmaceutical company’s stock valued at $132,000 after acquiring an additional 62,549 shares during the last quarter. State Street Corp boosted its holdings in shares of Regulus Therapeutics by 3.5% during the third quarter. State Street Corp now owns 1,000,998 shares of the biopharmaceutical company’s stock worth $1,572,000 after purchasing an additional 33,496 shares during the period. Finally, Victory Capital Management Inc. grew its stake in shares of Regulus Therapeutics by 10.4% in the third quarter. Victory Capital Management Inc. now owns 398,866 shares of the biopharmaceutical company’s stock worth $626,000 after purchasing an additional 37,480 shares during the last quarter. 92.38% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and issued a $10.00 price objective on shares of Regulus Therapeutics in a report on Monday, November 11th. One analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the stock. According to MarketBeat, Regulus Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $10.80.

Regulus Therapeutics Price Performance

RGLS stock opened at $1.00 on Monday. The stock has a market capitalization of $65.50 million, a P/E ratio of -0.93 and a beta of 1.60. The business has a fifty day moving average price of $1.46 and a 200-day moving average price of $1.54. Regulus Therapeutics Inc. has a 1-year low of $0.83 and a 1-year high of $3.79.

Regulus Therapeutics (NASDAQ:RGLS) last issued its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.03). As a group, analysts anticipate that Regulus Therapeutics Inc. will post -0.88 earnings per share for the current year.

Insider Buying and Selling

In other news, CEO Joseph P. Hagan purchased 50,000 shares of the company’s stock in a transaction that occurred on Thursday, January 30th. The stock was purchased at an average cost of $1.09 per share, with a total value of $54,500.00. Following the purchase, the chief executive officer now owns 260,808 shares in the company, valued at approximately $284,280.72. This trade represents a 23.72 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Crispina Calsada sold 38,716 shares of the stock in a transaction on Monday, January 13th. The stock was sold at an average price of $1.26, for a total value of $48,782.16. Following the completion of the sale, the chief financial officer now owns 50,566 shares in the company, valued at approximately $63,713.16. The trade was a 43.36 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 223,998 shares of company stock worth $282,237. 4.35% of the stock is owned by insiders.

Regulus Therapeutics Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.